Kathryn Clerici is an associate in Goodwin’s nationally recognized Life Sciences group, counseling clients in the industries of biotechnology and pharmaceuticals. Kathryn works with companies throughout the full range of the corporate life cycle. She represents clients in initial public offerings and capital markets transactions, startup and formation matters, venture capital financings, mergers and acquisitions, and other complex transactions. She also represents a number of publicly traded biotechnology companies in ongoing SEC compliance and corporate governance matters.
Experience
Kathryn’s recent client representations include:
- Rapport Therapeutics in connection with day-to-day governance and reporting matters, and its $174.4 million initial public offering and concurrent private placement
- BeiGene in connection with day-to-day governance and reporting matters, its $3.5 billion initial public offering on STAR Market of the Shanghai Stock Exchange in China, and its $2.08 billion registered direct offering
- Aerovate Therapeutics in connection with day-to-day governance and reporting matters, its $139.8 million initial public offering, and its “at-the-market” program
- Adicet Bio (formerly resTORbio) in connection with day-to-day governance and reporting matters, the merger between Adicet Bio and resTORbio, its “at-the-market” programs, and multiple follow-on offerings and private placement
- Cullinan Oncology in its $287.4 million initial public offering
- Forma Therapeutics in connection with its $319.3 million initial public offering, $275.8 million follow-on public offering, “at-the-market” program, and $1.1 billion sale to Novo Nordisk
- Theseus Pharmaceuticals, Inc. in its definitive acquisition by Concentra Biosciences, LLC
- Black Diamond in the spinout of Launchpad Therapeutics
- Alkermes Pharmaceuticals in the spin-off of its oncology business into Mural Oncology
- LumiraDx in its merger with CA Healthcare Acquisition Corp and listing on Nasdaq
- Absci Corporation in its $86.4 million follow-on offering
- Avadel Pharmaceuticals in its $125 million follow-on offering, “at-the-market” program, and $65 million private placement
- bluebird bio in its $575 million follow-on offering
- Argenx NV in its $557 million follow-on offering
- Slack in its acquisition by Salesforce
- The underwriters in Acrivon Therapeutics’ $99.4 million initial public offering and concurrent private placement
- The underwriters in IBEX’s $90.5 million initial public offering
- The underwriters in Pandion Therapeutics’ $135 million initial public offering
- Triveni Bio (formerly Amagma Therapeutics) in connection with day-to-day governance, its $92 million Series A financing, and its $115 million Series B financing
- Sail Bio (formerly LARONDE) in connection with day-to-day governance, its $440 million Series B financing, and its merger with Senda Biosciences
- Repertoire Immune Medicines in its $189 million Series B financing
- Forma Therapeutics in its $100 million Series D financing
- AsclepiX Therapeutics in its $35 million Series A financing
Professional Activities
Kathryn is a member of the Boston Bar Association.
Professional Experience
While attending law school, Kathryn worked as a corporate summer associate at Goodwin and a litigation summer associate at LibbyHoopes, P.C. in Boston. She was also an executive senior editor and a staff writer for the Boston College Law Review.
Credentials
Education
JD2019
Boston College Law School
(magna cum laude, Order of the Coif)
BArts&Sc2016
Boston College
Admissions
Bars
- Massachusetts
- New Hampshire